From Beginning To End, FDA Transparency Weighed On Sharfstein’s Mind
Executive Summary
As a lead player in FDA’s Transparency Initiative, outgoing Principal Deputy Commissioner Joshua Sharfstein helmed a task force that, on his penultimate day at the agency, unveiled a slew of measures to increase industry access to pertinent regulatory information.
You may also be interested in...
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Roxane's Redesigned Morphine Carton Reflects Orderly Rollout After Safety Concern
FDA allows existing stock to be used up over the course of a year after the new color-coded container for the high-potency product was approved.
FDA’s Unapproved Drugs Policy Draws Legal, Regulatory Responses From Lannett, To Little Success
Generic drug maker Lannett Co. is taking a two-pronged approach in responding to FDA’s unapproved drugs initiative, seeking regulatory approval of a previously unapproved opioid product while simultaneously suing the agency in federal court.